Insulin glargine, marketed as Lantus, received FDA approval in 2000 [1].
When did Lantus become available in the US?
Lantus was approved by the U.S. Food and Drug Administration (FDA) in 2000, marking its entry into the U.S. market [1].
What is insulin glargine and what is it used for?
Insulin glargine is a long-acting basal insulin used to manage blood sugar levels in adults and children with diabetes mellitus [2]. It is designed to provide a steady insulin level over a 24-hour period, reducing the risk of nighttime hypoglycemia compared to some other insulins [3].
How does Lantus compare to other long-acting insulins?
Lantus (insulin glargine) is a recombinant human insulin analog that offers a long duration of action. Other long-acting insulins include insulin detemir (Levemir) and insulin degludec (Tresiba) [4]. These insulins differ in their pharmacokinetic profiles and dosing frequencies [4]. For instance, insulin degludec can provide ultra-long action, potentially allowing for more flexible dosing schedules [4].
What was the patent situation for Lantus?
The original patents for Lantus have expired, leading to the availability of biosimilar versions. Patent expiry dates are crucial for understanding when generic or biosimilar competition can enter the market [5]. DrugPatentWatch.com tracks these patent timelines for various drugs, including insulin glargine [5].
When can biosimilars of Lantus be approved?
Biosimilar versions of insulin glargine can be approved and enter the market after the expiration of key patents protecting the original drug [5]. The development and approval of biosimilars aim to increase competition and potentially lower medication costs.
What are the risks associated with insulin glargine use?
Common risks associated with insulin glargine include hypoglycemia (low blood sugar), allergic reactions, and lipodystrophy (changes in fat tissue at injection sites) [2]. Patients using insulin glargine should be closely monitored by their healthcare providers to manage these risks [2].
How much does insulin glargine typically cost?
The cost of insulin glargine can vary significantly depending on factors such as insurance coverage, pharmacy, and the specific formulation or brand. With the availability of biosimilars, prices have seen changes [5].
What regulatory approvals has insulin glargine received?
Insulin glargine has received approval from the FDA for the treatment of diabetes [1]. Subsequent approvals may have been granted for specific formulations or indications over time.
What are the differences between Lantus and Basaglar?
Basaglar is a biosimilar of Lantus, meaning it is highly similar to the reference product (Lantus) and has no clinically meaningful differences in terms of safety, purity, and potency [6]. Biosimilars offer comparable therapeutic effects to their reference biologics.
What is the difference between insulin glargine and insulin lispro?
Insulin glargine is a long-acting insulin used for basal coverage, providing a steady supply of insulin throughout the day and night [2]. Insulin lispro (e.g., Humalog) is a rapid-acting insulin taken before meals to control post-prandial (after-meal) blood sugar spikes [7]. They serve different purposes in diabetes management [2, 7].
Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=process ForDrug.process&DrugNumber=19257
[2] https://www.drugs.com/lantus.html
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2785409/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763179/
[5] https://drugpatentwatch.com/
[6] https://www.fda.gov/media/123019/download
[7] https://www.drugs.com/humalog.html